Parexel International, a global biopharmaceutical services provider, has appointed Dr. Tracy Tsuetaki as senior vice president for peri/post-approval services and Parexel consulting. He will oversee the strategy and operational management for both businesses. He also will be on Parexel's business review committee.
Tsuetaki joins Parexel from UnitedHealth Group, where he was group president for Optum Life Sciences. He managed the strategic regulatory and safety services organization. This encompassed pharmacovigilance, medical information, pharmacoepidemiology, risk evaluation and risk mitigation strategies. It also included regulatory affairs consulting and operations outsourcing, chemical manufacturing and control, good clinical practice and good manufacturing practice services.
Previously, he was group president of i3—Clinical Development Services, also at United Healthcare Group. He led phase I-III clinical research and strategic regulatory offerings, as well as resourcing and staffing services.